CK2alpha V66A/I174A-HA (pJD23)
Full plasmid sequence is not available for this item.
|Item||Catalog #||Description||Quantity||Price (USD)|
|Plasmid||37362||Standard format: Plasmid sent in bacteria as agar stab||1||$85|
This material is available to academics and nonprofits only.
- Backbone size w/o insert (bp) 5542
- Total vector size (bp) 7000
Vector typeMammalian Expression
Selectable markersNeomycin (select with G418)
Growth in Bacteria
Bacterial Resistance(s)Ampicillin, 100 μg/mL
Copy numberHigh Copy
Gene/Insert nameCK2α V66A/I174A
Alt nameCasein Kinase II alpha
SpeciesH. sapiens (human)
Insert Size (bp)1470
Entrez GeneCSNK2A1 (a.k.a. CK2A1, CKII, Cka1, Cka2, OCNDS)
- Promoter CMV
/ Fusion Protein
- HA X3 (C terminal on insert)
- Cloning method Restriction Enzyme
- 5′ cloning site HindIII (not destroyed)
- 3′ cloning site ApaI (not destroyed)
- 5′ sequencing primer CMV-F
- 3′ sequencing primer BGH-rev (Common Sequencing Primers)
Terms and Licenses
- Not Available to Industry
- Zeocin® is an InvivoGen trademark.
there is a 3bp deletion (AGG) in the MCS 131.
These plasmids were created by your colleagues. Please acknowledge the Principal Investigator, cite the article in which the plasmids were described, and include Addgene in the Materials and Methods of your future publications.
For your Materials & Methods section:CK2alpha V66A/I174A-HA (pJD23) was a gift from David Litchfield (Addgene plasmid # 37362 ; http://n2t.net/addgene:37362 ; RRID:Addgene_37362)
For your References section:An unbiased evaluation of CK2 inhibitors by chemoproteomics: characterization of inhibitor effects on CK2 and identification of novel inhibitor targets. Duncan JS, Gyenis L, Lenehan J, Bretner M, Graves LM, Haystead TA, Litchfield DW. Mol Cell Proteomics. 2008 Jun;7(6):1077-88. Epub 2008 Feb 7. 10.1074/mcp.M700559-MCP200 PubMed 18258654